Glaucoma is the leading cause of irreversible blindness in Africa. The condition is treatable but not curable. There are numerous obstacles to glaucoma care in Africa, including availability, accessibility and affordability of treatments, as well as medication nonadherence among patients. Medical therapy is costly relative to the average income in Africa and it requires daily self-dosing by patients. Surgery is of limited availability in many regions in Africa, and a high proportion of patients refuse surgery because it is expensive. Selective laser trabeculoplasty (SLT) proves to be a favorable alternative to medical or surgical care, as it is highly effective and safe in people of African descent, more cost-effective than medical therapy, quick and easy to perform, and portable. The procedure also requires no postoperative care, thus obviates the issue of nonadherence. In uncontrolled studies, SLT has a high response rate and it lowers intraocular pressure by 30% to 40%, which exceeds the goal in international guidelines for initial therapies. The African Glaucoma Consortium (AGC), a member-driven stakeholder collective, has been formed in part to develop the infrastructure for continent-wide improvements in glaucoma care. It embraces SLT as a potential key tool in their development plans. The mission of AGC includes improving clinical care by educating existing and new health care professionals to expand the provider network, by conducting trials to identify optimal care strategies for glaucoma in Africa, and by facilitating the development of an integrated network of Centers of Excellence to bring SLT and other crucial glaucoma therapies to communities throughout Africa.
The high prevalence of glaucoma in Africa can be explained largely by genetics, as described by Allingham 4 in the 2017 American Glaucoma Society's Clinician-Scientist Lecture. The high prevalence of glaucoma blindness is likely attributable to the numerous barriers to treatment in Africa and other developing countries. The most important of these are limitations in availability, affordability and acceptability of treatments, along with a widespread lack of awareness of the disease itself. 5, 6 Because glaucoma is generally asymptomatic in its early and moderate stages, many affected individuals do not seek care until the advanced stages, and very often after irreversible blindness in 1 eye. 7 Treatments for glaucoma share in common the reduction of intraocular pressure (IOP), a well-established causal risk factor for POAG 8 and its progression. 9 Reduction of IOP can be achieved using topical medications, by laser therapy, and through surgical procedures. Medical therapy is impractical in many regions of Africa on the basis of cost alone. Lack of widespread availability also limits its use. Perhaps the most important barrier to medical therapy for glaucoma is nonadherence. There are many reasons for nonadherence to medical therapy for glaucoma and this issue is complex. 10, 11 Therapy neither relieves symptoms nor restores lost vision, rendering its benefit in preventing further loss of sight difficult for many patients to perceive. Surgical interventions to lower IOP can effectively stabilize glaucoma and prevent further vision loss. 12 Access to surgery is limited by its high cost and a paucity of surgeons trained to perform the procedures, which require intensive postoperative care. Further, surgical intervention has very low acceptance rates (less than 10%) among glaucoma patients in low-and middle-income countries, 13 where they are usually presented at an advanced stage. When they expect their lost vision to be restored but instead being offered surgery in the remaining sighted eye to preserve its vision, they frequently refuse.
There remains substantial unmet need for a glaucoma treatment that is effective, safe, cost-effective, widely available, and acceptable to patients early in the disease course, before the permanent loss of central visual acuity. Selective laser trabeculoplasty (SLT) may address this unmet need for many patients with POAG in Africa. The procedure is minimally invasive, easy to perform without the need for glaucoma subspecialty training, highly effective and safe in people of African descent, and cost-effective compared with medical therapy. Besides, it requires no postoperative care or medications, and can be performed using portable equipment that can be shared among many clinical centers. In this review, we present the evidence for the efficacy, safety and cost-effectiveness of the procedure, and describe ongoing efforts to establish a platform to expand access to SLT throughout Africa.
The role of SLT in the management of glaucoma in the developed world has not been fully elucidated. Numerous investigators have evaluated its IOP-lowering efficacy when used adjunctively to medications, as a replacement for medical therapy, and as primary therapy.
The seminal report of the efficacy and safety was authored by Latina et al, 14 who are the developers of the SLT technology. In this study, SLT was performed over 180 degrees of the trabecular meshwork in 1 eye each of 53 subjects with uncontrolled POAG on maximal medical therapy. A mean IOP reduction of 6 mm Hg was observed, and 70% of eyes manifested an IOP reduction of 3 mm Hg or more at 6 months. Since this initial report, many additional studies have been published evaluating the additive IOP reduction seen when SLT is performed on eyes receiving medical therapy. In general, these studies revealed that SLT used adjunctively to medical therapy (180 or 360 degrees) provides incremental mean IOP reductions in the range of 4-6 mm Hg. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] As clinicians became familiar with SLT, its role in glaucoma management expanded. 27 Patients whose glaucoma was controlled on 1 or more medication were offered SLT as a means of reducing the medication burden. Francis et al 28 reported a retrospective analysis in which 180-degree SLT reduced the medication burden by a mean of 2.1 medications at 6 months and 1.3 medications at 12 months, while maintaining IOP at pre-SLT levels. Three subsequent prospective studies have confirmed this magnitude of effect with 180-, 270-, and 360-degree SLT. [29] [30] [31] Owing to its efficacy and safety profile, coupled with the elimination of the nonadherence associated with medical therapy, SLT's role as primary therapy for POAG has also been evaluated. McIlraith et al 32 conducted a prospective nonrandomized trial comparing 180-degree SLT with latanoprost monotherapy in 100 eyes of 61 patients with newly diagnosed and treatment-naive POAG or ocular hypertension. They reported a mean IOP reduction of 8.3 mm at 12 months in the SLT group and 7.7 mm Hg in the control group (P = 0.208). Subsequently, another group initiated a randomized trial to compare SLT with medical therapy. Although the study failed to complete enrollment and terminated early, the data at study termination were consistent with the findings of McIlraith et al's group: mean IOP reductions were 6.3 mm Hg in the SLT group and 7.0 in the medical (latanoprost) group. 33 The IOP-lowering effect of SLT wears off over time. 34 Multiple studies have now established beyond doubt that SLT can be safely and effectively repeated when its effect wanes. [35] [36] [37] [38] [39] [40] [41] Further, no adverse events related to SLT were identified in a cohort (SA Gandolfi, oral communication, April 2018) that underwent multiple 360-degree treatments over a 10-year period. 42 These studies consistently demonstrate that repeat SLT restores IOP to the same level achieved by initial SLT with no increase in adverse events compared with the first SLT, and in many cases, the IOP-lowering effect of repeat SLT endures longer than the initial treatment.
The safety of SLT has been evaluated in many studies and comprehensively reviewed. 43 Among the more common complications is transient anterior chamber inflammation, which occurs in up to 83% of eyes, consisting mostly of increased cells in the aqueous humor, and is typically self-limited. Cases of true uveitis requiring anti-inflammatory therapy are rare. Less common are IOP elevations after treatment, estimated to occur in less than 5% of eyes. These tend to be transient and self-limited in nature. In heavily pigmented eyes, such as those with pigment dispersion syndrome, there may be an increased risk for a significant and sustained IOP elevation that may require surgical intervention. Rare complications include hyphema and macular edema, reports of which are limited to only a few cases each. In recent years, several cases of corneal stromal edema have been reported in eyes undergoing SLT. These are often associated with a hyperopic shift manifesting as blurred vision. [44] [45] [46] [47] [48] [49] In most reported cases, the corneal haze cleared and refraction normalized, although a few cases of sustained hyperopic shifts have been reported. 46, 48 To summarize the growing body of literature on its efficacy and safety, SLT can be utilized as primary therapy, replacement therapy and adjunctive therapy, delivering IOP reductions consistent with prostaglandin analog therapy. Safety issues are typically transient and self-limited, and sight-threatening complications, although rare, have been reported.
SELECTIVE LASER TRABECULOPLASTY IN AFRICAN-DERIVED EYES
The characteristics of SLT ensure its selective absorption by pigmented cells in the trabecular meshwork. On this basis, Realini 50 postulated that the efficacy and safety profiles described in largely European-derived eyes may not fully characterize outcomes in the eyes of African-derived people. A cohort of 61 African-derived patients with POAG in Saint Lucia underwent bilateral 360-degree SLT after washout of all topical IOPlowering therapy. The mean IOP was approximately 21 mm Hg after washout. From this baseline, mean IOP reductions of 7-8 mm Hg (35-40%) were seen in the first 12 months of follow-up. Interestingly, the majority of patients in this series reported photophobia within 1 day of SLT and lasting 2-4 days on average; most cases were mild or moderate, but a few cases were severe. All cases of photophobia resolved without intervention within 1 week of treatment. This unexpected adverse effect was not reported in prior SLT studies.
On the basis of this preliminary study, a multicenter Caribbean SLT study was undertaken. The West Indies Glaucoma Laser Study enrolled 72 patients with POAG of African descent at 2 sites in Saint Lucia and 1 site in Dominica. 51 Subjects underwent washout of all medications followed by a 2-day determination of baseline IOP (minimum of 2 measurements each day) before undergoing bilateral 360-degree SLT. At 12 months post-SLT, the mean IOP reduction was 6.5 mm Hg (30%), and 78% of treated subjects maintained a minimum IOP reduction of 20% without the need for further IOP-lowering interventions. To characterize the potential effects of regression to the mean on the results of this uncontrolled study, a stepped-wedge study was conducted in which subjects were randomly assigned to undergo immediate versus delayed washout and treatment. Those in the delayed group continued the same medical IOP-lowering therapy as at enrollment. Intraocular pressure remained unchanged in these eyes from enrollment to eventual washout, demonstrating no appreciable regression to the mean. Significantly, SLT was shown to be safely and effectively repeatable in this population when its effect wore off. 52 Common adverse events included photophobia (37.5%), eye pain (30.6%), and headache (15.3%); only 3 eyes of 2 subjects (2.8%) manifested an IOP elevation greater than 5 mm Hg, both of which resolved within 1 week with topical IOP-lowering medication. One eye developed brief corneal stromal edema and blurred vision that resolved completely without intervention.
In addition to the above 2 prospective studies, 51, 52 2 retrospective studies of SLT in black Africans with glaucoma have been reported. 53, 54 In the first study, 69 eyes of 40 Senegalese subjects with POAG or ocular hypertension underwent 180-degree SLT, and if an IOP reduction was observed, the remaining 180 degrees were treated within 1 month. 53 The mean IOP reductions of 30% were reported, with 90% of treated eyes manifesting clinically meaningful IOP reductions. Overall, 60% of patients on prostaglandin monotherapy were able to discontinue medication use, and 25% of patients on multidrug regimens were able to discontinue 1 or more medications. In the second study, 148 eyes of 84 subjects underwent SLT; of these, 60 were black, 21 were Indian, and 3 were white. 54 At 12 months post-SLT, the mean IOP reductions were 42% in black subjects and 28% in nonblack subjects (P < 0.001), and 90% of black subjects maintained a minimum IOP reduction of 20% without further interventions at 12 months.
To summarize the existing literature on SLT in Africanderived people with glaucoma, the mean IOP reductions at 12 months were approximately 30% to 40% (Fig. 1 50-54 ), with 80 to 90% of patients maintaining a minimum IOP reduction of 20% 1 year after treatment. Transient photophobia is common and self-limited and may be unique to this population.
COST-EFFECTIVENESS OF SELECTIVE LASER TRABECULOPLASTY IN GLAUCOMA MANAGEMENT
In many developed countries, efficacy and safety drive treatment patterns. In developing regions however, the viability of a treatment is driven largely by cost. 6 Indeed, a treatment that cures glaucoma would likely have little impact on Africa's disease burden owing to the associated high cost. Medical therapy has low up-front costs that are amortized over the course of therapy, but its effectiveness (ie, cost-effectiveness) is limited by nonadherence. Many patients with glaucoma fail to take their medications as prescribed, 55 contributing to inadequate IOP control and progression of disease. This issue compromises therapy with any glaucoma medication, regardless of its cost.
There is a relative paucity of data on the cost-effectiveness of SLT versus other treatment modalities, particularly in lowresource settings such as Africa. Generalizing data from developed regions to the developing world is of limited value. From an effectiveness standpoint, there is preliminary evidence that SLT may have a different efficacy 54 and safety 51 profile in people of African versus non-African descent. Likewise, from a cost perspective, the cost of medical procedures (eg, laser) is likely to be disproportionately more expensive in developed compared with developing regions, far more than the difference in cost of medications between these 2 regions.
The ideal cost-effectiveness analysis should be derived from a randomized clinical trial, but none exists so far. A case-control study analyzed data from a managed care database of 1145 patients with POAG receiving laser trabeculoplasty in the United States between 1998 and 2005. 56 This study reported that laser trabeculoplasty was associated with higher total ophthalmologyrelated charges over the course of 1 year (US$1364 versus US$30 for patients not undergoing SLT). However, this study has numerous limitations. Its timeframe predates the commercialization of SLT so only argon laser trabeculoplasty (ALT) cases were included in its analysis. Although SLT and ALT have similar efficacy, [57] [58] [59] [60] [61] there are likely differences in the repeatability and the patterns of adjuvant therapy. In addition, laser trabeculoplasty was presumably not used as primary therapy for most of these patients, and the economics of laser trabeculoplasty as adjunctive therapy is likely different from that in primary therapy. Patients were not randomized to treatments, so potential selection bias may exist. Also, the study duration was limited to 1 year. If the IOP-lowering effect of SLT lasts longer than 1 year, the long-term cost savings of SLT versus medications may not be adequately represented in this analysis. In fact, a separate study suggested that the time to cost-effectiveness of SLT over generic prostaglandin therapy was 13.1 months. 62 This is meaningful given that in a long-term follow-up of patients with POAG undergoing SLT in Saint Lucia, the 5-year medication-free survival rate with a minimum IOP reduction of 20% was approximately 70% after a single SLT treatment. 63 In the absence of real-world data, modeling is a useful strategy to evaluate cost-effectiveness. Stein et al 64 compared the cost-effectiveness of laser trabeculoplasty with medications in newly diagnosed open-angle glaucoma patients. They compared 3 cohorts (no treatment, prostaglandin analog, and laser trabeculoplasty) based on progression rates from the Early Manifest Glaucoma Trial (EMGT) and the Glaucoma Laser Trial (GLT), along with cost data from the 2010 United States Medicare fee schedule. A Markov model assessed incremental costs as patients progressed through 5 stages of disease, from mild POAG to bilateral blindness, based on progression rates from the EMGT. Costs included visits, therapies, testing, and low vision aids. Quality of life gained from reducing vision loss was also assessed, and quality-adjusted life years (QALY) gained was calculated for each cohort. The study reported that the incremental cost per QALY was higher for laser trabeculoplasty than prostaglandin analogs, but small changes in the model could easily shift the economics in favor of laser. For example, a 25% decrease in medication efficacy (eg, due to poor adherence) would result in trabeculoplasty being more cost-effective. Caveats must be considered when applying these results to Africa: costs were based on United States health economics, progression rates were based on the majority of white patients in the EMGT study population, and efficacy was based on the GLT which utilized ALT rather than SLT. In an effort to address these issues, Wittenborn and Rein 65 modeled the cost of glaucoma care in Barbados and Ghana, 2 Africanderived populations with vastly different economic status. Using glaucoma progression rates specific to African-derived glaucoma in the Barbados Eye Study, they evaluated the cost-effectiveness of 2 approaches to POAG: adherence to the American Academy of Ophthalmology's preferred practice pattern for POAG, or 1-time trabeculoplasty. For a developed country like Barbados, all intervention scenarios were found to be highly cost-effective. However, for a developing country like Ghana, only the 1-time trabeculoplasty approach was cost-effective. One caveat of this study is its cost-effectiveness was driven in part by years of life affected by glaucoma, which was much lower in Ghana due to the higher mortality rate there.
To summarize the cost-effectiveness of SLT, research supports that under some conditions-such as medication nonadherence or health resource limitations-SLT may offer a more cost-effective approach to glaucoma management than medical therapy. Further research, preferably using real-world data in the regions of interest, will help clarify this issue over time. If the efficacy and safety of SLT seen in early studies can be confirmed in large multicenter African trials, robust cost-effectiveness data can drive the prioritization of investment into this technology to address the growing burden of glaucoma blindness in the region.
DEVELOPING AN EVIDENCE-BASED APPROACH TO GLAUCOMA CARE IN AFRICA
The development of an evidence-based strategy to reduce glaucoma blindness in Africa requires a comprehensive understanding of the severity of glaucoma at presentation, current treatment patterns, acceptability of treatment by patients, and relative efficacy and safety of the various treatment modalities in this population. In Africa, none of these areas have been well characterized.
The African Glaucoma Consortium (AGC) has recently been organized to address these knowledge gaps. The AGC (www.africanglaucoma.org) is a dedicated group of stakeholders including both doctors and scientists in and out of Africa working together to better understand and overcome the obstacles to glaucoma care in the region. Its mission is to reduce the burden of glaucoma blindness in Africa by creating consensus among stakeholders; building sustainable, regional capacity to deliver high-quality, low-cost care; and fostering demand for this care in communities.
The AGC is currently developing a series of studies to inform future practice patterns. The first of these is the Severity, Treatment, and Acceptance of Glaucoma thErapy (STAGE) study, which seeks to characterize the stage of glaucoma at the time of initial diagnosis, to describe current treatment practices, and to document acceptance of recommended therapy by patients and identify reasons for nonacceptance. An additional goal of the STAGE study is to develop an evidence-based glaucoma severity classification system relevant to glaucoma in Africa, where presentation is often delayed until central vision is lost in 1 eye. 66 Based on the premise that SLT can be a viable, cost-effective therapy for glaucoma in Africa, 2 studies are being developed to identify its optimal implementation. The Glaucoma Laser versus Incisional Surgery with Trabeculectomy to End Nerve Damage in Africa (GLISTEN Africa) study will compare SLT with incisional surgery in patients with moderate-to-advanced glaucoma. An innovative aspect of this randomized clinical trial is that patient acceptance of therapy will be factored into the efficacy analysis: subjects declining their randomized intervention will be included in outcomes assessments (IOP reduction, proportion of patients achieving prespecified target IOP, and so on). The second studythe African Glaucoma Laser Trial (AGLT)-will compare SLT with medical therapy in early-to-moderate glaucoma. The AGLT is planned as a multicenter clinical trial and will include sites in Africa that represent multiple ethnic populations to evaluate generalizability of results throughout the continent. This complements an ongoing single-site randomized clinical trial comparing the efficacy of primary SLT versus timolol in indigenous Africans with all stages of glaucoma in Tanzania. 67 Future studies under discussion by the AGC include potential comparisons of trabeculectomy with various minimally invasive glaucoma surgery (MIGS procedure), with the hope that the improved safety and ease of performing the MIGS procedure may offset the anticipated additional costs associated with it. Also under discussion is the development of an efficient approach to screening for glaucoma, as 90% or more of glaucoma in Africa remains undiagnosed. [68] [69] [70] The AGC also hopes to develop evidence-based treatment guidelines specific to African glaucoma upon completion of these and other future studies. The results of these ongoing and future trials will provide more evidence for the use of SLT in sub-Saharan Africa where limited resources, including lack of availability and less affordability of drugs, pose additional constraints to the medical management of glaucoma. It is also hoped that the optimal surgical management of medically uncontrolled eyes can be clarified.
A PROPOSED MODEL OF GLAUCOMA CARE IN AFRICA
Glaucoma is a complex issue in Africa, in which its many subregions bring about different types of barriers to glaucoma care. The major challenges for the control of glaucoma include its high prevalence, low awareness, late presentation, abject poverty, limited healthcare resources, and paucity of data to guide evidence-based medical practice. Relative weighting of these factors varies with different subregions, as Africa is not a homogeneous one-size-fits-all population and the issues impeding glaucoma care are vastly different between rural and remote areas. Tremendous ethnic diversity throughout Africa also renders a single continent-wide approach impractical.
A conceptual framework for the delivery of glaucoma care in Africa is based on modification of an approach developed by the L V Prasad Eye Institute and endorsed by the World Health Organization as a global primary eye care strategy. 71 Such framework results in the AGC model (Fig. 2) , which is a multitiered, referral-based geocentric hierarchy of care. In this model, glaucoma care begins at the community level with its awareness integrated with broader primary health advocacy in local villages. Patients with eye diseases and their family members, healthcare workers, and motivated healthy laypeople serve as village-based vision ambassadors. They promote awareness of glaucoma and other blinding diseases, which are integrated into educational programs addressing broader themes such as nutrition, sanitation, and immunization. Eye health screening is also incorporated into multiphasic screenings for primary systemic conditions such as hypertension and diabetes.
In the AGC model, high-risk and screen-positive subjects from multiple villages are referred to a regional primary care center where they are evaluated by a vision technician. The regional primary care center is not a standalone facility, as it works in tandem with a vision technician who is trained to perform the 3 Rs: refraction, recognition, and referral. In addition to refraction, evaluation of patients should include anterior segment examination (ideally with a slit lamp but minimally with a penlight to detect cataract) and may also include tonometry and perimetry (perhaps using a tablet-based application 72 ). Patients with nonrefractive vision loss are referred by the vision technician to a regional primary eye care center with a physician-level eye care provider for definitive diagnosis. Such centers receive referrals from vision technicians at multiple regional centers and are trained to diagnose and treat many eye conditions. Uncomplicated cataract surgery may be encountered at this level of care. If glaucoma is diagnosed and medical therapy is deemed viable, the patient will be treated at this level. In most cases, however, laser or incisional intervention may be more appropriate for glaucoma care, patients will be referred to an eye care Center of Excellence (also applicable to other subspecialty surgical services such as retina, corneal transplantation, etc). Training programs for primary eye care may be incorporated into these sites. For optimal efficiency, the primary eye care provider has the option of communicating with a specialist via a smartphone-based telemedicine platform (such as Vula mobile, which has been used for remote dermatology consultation in South Africa 73 ) to assist with difficult diagnoses or management dilemmas. The eye care Center of Excellence provides definitive diagnosis and management of subspecialty eye conditions along with complex presentations of more general eye conditions (such as subluxed cataract or treatment-recalcitrant ocular infection). This Center is typically part of a tertiary multispecialty healthcare center to ensure the ability to comanage systemic comorbidities (such as diabetes). For glaucoma care, each Center of Excellence has a fellowship-trained glaucoma specialist and a well-equipped clinical and surgical facility (including access to lasers for trabeculoplasty, iridotomy, cilioablative procedures, and retinal applications along with an operating microscope, mitomycin C). Ideally, these Centers are affiliated with academic institutions, as some of the Centers will offer training programs for vision technicians, ophthalmology residents, and subspecialty fellows as appropriate. Training for vision technicians is critical as they may be managing postoperative care for many glaucoma patients, hence they need to understand the importance of accurate IOP assessment and recognition of sight-threatening complications to facilitate prompt referrals. The Centers can also participate in research activities, particularly those in urban areas serving a huge number of local patients who can be followed up without the need to travel long distances. A robust patient education program can also be incorporated into the care process for patients at Centers of Excellence, primary eye care centers, and primary care centers, because patients and family members seen at any level of this system can become a vision ambassador upon their return to village after treatment.
This framework integrates eye and vision health into a broader effort to improve overall health of the region. This approach provides efficiency by utilizing existing healthcare infrastructure, programs, and outreach. Our model brings primary eye care to both urban areas and remote villages, and provides an established referral network to ensure adequate care for all levels of ocular pathology. More importantly, the model unites care providers across large geographic areas, through both telemedicine connectivity and collaborative activities including multicenter outcomes research and the training of future eye care providers, thus expanding knowledge and regional eye care capacity. Equally important is the flexibility this program offers, as virtually all aspects of clinical care are easily adaptable to regional needs and resources without compromising the comprehensive approach to vision health. For instance, in areas with low population density, travelling to a Center of Excellence may be too burdensome, in which case SLT can be performed at primary eye care centers using portable SLT units.
CONCLUSIONS
The burden of glaucoma in Africa is enormous and growing. Treating glaucoma and preventing blindness are hampered by many obstacles, including high prevalence, lack of awareness, and limited human and monetary resources to provide treatment. Efficacy and safety must be considered in addressing glaucoma problem in Africa, and viable solutions depend very much on their cost-effectiveness. Medical therapy is arguably safest, but the need for lifelong daily therapy is cost prohibitive. Surgical therapy most effectively lowers IOP and stabilizes glaucoma, but it is costly, has significant sight-threatening complications, and is of limited availability in many parts of Africa. Selective laser trabeculoplasty has shown promise in several studies as a safe and effective means of lowering IOP in glaucoma eyes of African derivation. The magnitude of IOP reduction provided by SLT in this population (30-40% through 12 months of follow-up) would reasonably be expected to slow or halt the progression of glaucoma. The AGC is initially motivated to develop a platform for SLT delivery in Africa, it is now building a continent-wide multilevel eye care and visual health system, integrated with existing primary and eye care infrastructure, to enhance and expand vision-saving healthcare in the region. The AGC is dedicated to improving clinical care, conducting impactful outcomes research, and training future eye care providers to expand capacity in the region.
